Core Insights - Sotera Health Company (SHC) reported revenue of $294.34 million for the quarter ended June 2025, reflecting a year-over-year increase of 6.4% [1] - The earnings per share (EPS) for the quarter was $0.20, up from $0.19 in the same quarter last year, exceeding the consensus EPS estimate of $0.17 by 17.65% [1] - The reported revenue surpassed the Zacks Consensus Estimate of $276.08 million, resulting in a surprise of 6.61% [1] Financial Performance Metrics - Sotera Health's segment revenues included Sterigenics at $194.84 million, exceeding the average estimate of $184.48 million by 10.5% year-over-year [4] - Nelson Labs reported revenues of $57.07 million, slightly above the average estimate of $56.73 million, but down 3.3% year-over-year [4] - Nordion's revenues were $42.43 million, surpassing the average estimate of $34.95 million with a year-over-year increase of 2.9% [4] Segment Income Analysis - Segment income for Sterigenics was reported at $107.75 million, exceeding the average estimate of $100.36 million [4] - Nelson Labs achieved segment income of $19.51 million, above the estimated $17.53 million [4] - Nordion's segment income was $23.48 million, significantly higher than the average estimate of $18.62 million [4] Stock Performance - Shares of Sotera Health have declined by 5.6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 1.9% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]